Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen women in Executive Roles (legacy ESG report disclosure) (%) (%)
Amgen Sustainability Report
Latest, FY2023
44.0%
Period ended Dec 31, 2023
Change on a year earlier
-1.0 pts
45.0% in FY2022
History
5 years
Since FY2019
Sources
1
https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Women in Executive Roles (legacy ESG report disclosure) (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 44.0% | -1.0 pts | https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf ↗ |
| FY2022 | Dec 31, 2022 | 45.0% | +1.0 pts | https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf ↗ |
| FY2021 | Dec 31, 2021 | 44.0% | +2.0 pts | https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf ↗ |
| FY2020 | Dec 31, 2020 | 42.0% | +3.0 pts | https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf ↗ |
| FY2019 | Dec 31, 2019 | 39.0% | – | https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf ↗ |
Cite this data
StockData. (2026). Amgen Women in Executive Roles (legacy ESG report disclosure) (%) (%), annual FY2019–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/esg_div_women_exec
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.